# Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Source: https://onco.cc/trials/nct07011654/  
OnCo record `nct07011654` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of sacituzumab govitecan and naxitamab in triple-negative breast cancer, run by M.D. Anderson Cancer Center, now recruiting.

## Summary

Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) is a phase 1/2, interventional study registered as NCT07011654 by M.D. Anderson Cancer Center, with a registry enrolment figure of 31 participants, started 2025-09-19 and due to reach its primary completion in 2028-07-01. Interventions recorded: Sacituzumab govitecan; Naxitamab. Conditions listed: Metastatic Triple-Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Histologically confirmed metastatic TNBC". Sites: United States. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07011654
- Phase: 1/2
- Setting: Phase I/II Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)
- Sponsor: M.D. Anderson Cancer Center
- Enrolled: 31

## Sources

- ClinicalTrials.gov NCT07011654: https://clinicaltrials.gov/study/NCT07011654

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Naxitamab](https://onco.cc/drugs/naxitamab/), [Sacituzumab govitecan](https://onco.cc/drugs/sacituzumab-govitecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07011654.json